Trump announces trade deal with EU following months of negotiations
Catherine T. Doherty, Executive Vice President of Regional Businesses at Quest Diagnostics Inc. (NYSE:DGX), has recently sold a significant portion of her shares in the company. According to a recent SEC filing, Doherty sold 5,370 shares of Quest Diagnostics common stock at a price of $174.13 per share. This transaction, completed on March 5, 2025, was executed under a pre-established Rule 10b5-1 sales plan, resulting in a total transaction value of $935,078. The sale comes as Quest Diagnostics, now valued at $19.43 billion, trades near its 52-week high of $178.09.
Following this sale, Doherty retains direct ownership of 68,068 shares in the company. Additionally, she holds an indirect interest in 4,427 shares through the company’s 401(k) and Supplemental Deferred Compensation Plan, as reported by the plan administrator. The shares within these plans are periodically acquired and are based on the account balance of the company’s stock fund. According to InvestingPro analysis, the stock currently appears overvalued, trading at a P/E ratio of 22.51.
This transaction highlights the ongoing management of personal portfolios by company executives and provides insight into the financial movements within Quest Diagnostics. InvestingPro data shows the company maintains a strong financial health score, with particularly robust metrics in profitability and price momentum. Discover 8 additional exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Quest Diagnostics reported a strong performance for the fourth quarter of 2024, with adjusted earnings per share (EPS) reaching $2.23, surpassing the forecast of $2.19. The company’s revenue also exceeded expectations, hitting $2.62 billion compared to the anticipated $2.58 billion. Quest Diagnostics saw a 14.5% year-over-year increase in consolidated revenues, driven by growth in advanced diagnostics and preventative health services. In response to the earnings release, JPMorgan raised its price target for Quest Diagnostics from $173 to $180, while maintaining a Neutral rating, citing the solid performance of the company’s clinical lab operations.
Conversely, Citi downgraded Quest Diagnostics from Buy to Neutral, setting a new price target of $185. Citi analysts expressed concerns over margin pressures and earnings growth prospects, particularly due to challenges from LifeLabs and the launch of Haystack. Despite these concerns, Quest Diagnostics continues to invest in IT and automation to enhance its service offerings. The company projects 2025 revenue between $10.7 billion and $10.85 billion, with an expected organic growth rate of about 3%. These developments reflect the dynamic landscape Quest Diagnostics is navigating, as it balances strategic initiatives with financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.